Buckeys, the next one to hold the IP in hock would be Eastern. A small amount to pay ($7MM) to insure the IP doesn't fall into the hands of HepaLink if nothing else, just out of sheer principle. 

And I can't see Hepa and Ori team up to take advantage of a bad situation as it would appear as a conflict of interest, both of them holding BODs positions, don't you think?

And for the life of me, I can't understand why Hepalink doesn't conduct a parallel open-label Covid-19 clinical trial in China at their expense, as they do hold a licence for Apabetalone.

IMO ... Koo